騰盛博藥-B(02137.HK):在接受兩次BRII-835 (VIR-2218)給藥後 中國慢性HBV感染患者的HBV表面抗原水平呈劑量依賴性降低
格隆匯3月31日丨騰盛博藥-B(02137.HK)發佈公吿,公司今日在2022年亞太肝臟研究學會第31屆會議上,公佈了其臨牀階段小干擾核糖核酸(siRNA)BRII-835 (VIR-2218)在中國慢性乙型肝炎病毒(HBV)感染患者中進行的一項二期隨機、雙盲、安慰劑對照試驗的最新數據,該會議於3月30日至4月3日期間通過線上形式在韓國首爾舉行。
數據顯示,在接受兩次BRII-835 (VIR-2218)給藥後,中國慢性HBV感染患者的HBV表面抗原(HBsAg)水平呈劑量依賴性降低,並且在乙肝E抗原陰性(HBeAg-)和乙肝E抗原陽性(HBeAg+)患者中HBsAg水平降低程度相近。此外,BRII-835 (VIR-2218)耐受性良好,所有治療期間出現的不良事件均為輕或中度,未觀察到具有顯著臨牀意義的丙氨酸氨基轉移酶升高。
首都醫科大學附屬北京友誼醫院肝病研究中心賈繼東教授表示:“在本研究中,BRII-835 (VIR-2218)兩次給藥後,HBeAg-和HBeAg+中國慢性HBV感染患者的血清HBsAg水平呈劑量依賴性降低,這與之前在其他人種╱種族中的研究結果一致。在這些數據的支持下,公司認為BRII-835 (VIR-2218)這類可降低由慢性HBV感染引起的高病毒抗原負荷的新型藥物,有潛力成為慢性HBV功能性治癒方案的基石,從而有助解決慢性HBV感染所帶來的全球性重大公共衞生問題”。
騰盛博藥首席醫學官嚴立博士表示:“開發慢性HBV功能性治癒方案是騰盛博藥的目標之一。公司正在進行多項研究以評估不同的聯合治療方案,公司很高興本研究的數據支持siRNA作為聯合治療方案的骨幹的潛力。公司期待在今年底能夠從這些研究中看到有關BRII-835 (VIR-2218)與其他藥物聯合使用的更多數據”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.